Mast cells, eosinophils and fibrosis

Clinical and Experimental Allergy, Supplement

Volumn 27, Issue 1, 1997, Pages 64-70

  Levi Schaffer, F ^a   Weg, V B ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

NEDOCROMIL SODIUM;

BONE MARROW TRANSPLANTATION; CELL INTERACTION; CONFERENCE PAPER; EOSINOPHIL; FIBROBLAST; FIBROSIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOGENESIS; MAST CELL; PRIORITY JOURNAL;

ANIMALS; CELLS, CULTURED; CHRONIC DISEASE; EOSINOPHILS; FIBROSIS; GRAFT VS HOST DISEASE; HUMANS; MAST CELLS;

EID: 0030954112     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Hawkins RA, Claman HN, Clark RA, Steigerwald JC. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 1985; 102:182-6.
2. Nishioka K, Kobayashi Y, Katayama I, Takijiri C. Mast cell numbers in diffuse scleroderma. Arch Dermatol 1987; 123:205-8.
3. Doyle JA. Eosinophilic fasciitis. Cutis 1984; 34:259-61.
4. Wichman BE. The mast cell count during the process of wound healing: an experimental investigation on rats. Acta Pathol Microbiol Scand 1955; 108(Suppl):1-35.
5. Persinger MA, Lepage P, Simard JP, Parker GH. Mast cell numbers in incisional wounds in rat skin as a function of distance, time and treatment. Br J Dermatol 1983; 108:179-87.
6. Haslam PL. Evaluation of alveolitis by studies of lung biopsies. Lung 1990; 168(Suppl):984-92.
7. Noguchi H, Kephart GM, Colby, TV, Gleich, GJ. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol 1992; 140:521-8.
8. Jeffery PK. Morphology of the airway wall in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143:1152-61.
9. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88:470-476.
10. Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am 1989; 73:1157-66.
11. Todd R, Donoff BR, Chiang T et al. The eosinophil as a cellular source of transforming growth factor alpha in healing cutaneous wounds. Am J Pathol 1991; 138:1307-13.
12. Mauch C, Krieg T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am 1990; 16:93-107.
13. Russel JD, Russel SB, Trupin KM. The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J Cell Physiol 1977; 93:389-93.
14. Hatamochi A, Fujiwara K, Ueki H. Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch Dermatol Res 1985; 277:60-4.
15. Banovac K, De Forteza R. The effect of mast cell chymase on extracellular matrix: studies in autoimmune thyroditis and in cultured thyroid cells. Int Arch Allergy Immunol 1992; 99:141-9.
16. Birkedal-Hansen H, Cobb CM, Taylor RE, Fullmer HM. Activation of fibroblast procollagenase by mast cell proteases. Biochim Biophys Acta 1976; 438:273-86.
17. Rochester CL, Ackerman SJ, Zheng T, Elias JA. Eosinophil-fibroblast interactions. Granule major basic protein interacts with IL-1 and transforming growth factor-β in the stimulation of lung fibroblast IL-6-type cytokine production. J Immunol 1996; 156:4449-56.
18. Hibbs MS, Mainardi CL, Kang AH. Type-specific collagen degradation by eosinophils. Biochem J 1982; 207:621-4.
19. Levi-Schaffer F, Austen KF, Caulfield JP, Hein A, Bloes WF, Stevens RL. Fibroblasts maintain the phenotype and viability of the rat heparin-containing mast cells in vitro. J Immunol 1985; 135:3454-62.
20. Levi-Schaffer F, Austen KF, Gravallese PM, Stevens RL. Co-culture of interleukin-3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci USA 1986; 83:6485-8.
21. Rothenberg ME, Owen WF, Silberstein DS et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest 1988; 81:1986-92.
22. Vancheri C, Gauldie J, Bienenstock J et al. Human lung fibroblast-derived granulocyte-macrophage colony stimulating factor (GM-CSF) mediates eosinophil survival in vitro. Am J Respir Cell Mol Biol 1989; 1:289-95.
23. Anwar AR, Moqbel R, Walsh GM, Kay AB, Wardlaw AJ. Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 1993; 177:839-43.
24. Clark RA. Cutaneous tissue repair: basic biologic considerations. I. J Am Acad Dermatol 1985; 13:701-25.
25. Levi-Schaffer F, Kupietzky A. Mast cells enhance migration and proliferation of fibroblasts into an in vitro wound. Exp Cell Res 1990; 188:42-9.
26. Norrby K. Evidence of mast-cell histamine being mitogenic in intact tissue. Agents Actions 1985; 16:287-90.
27. Jordana M, Befus AD, Newhouse MT, Bienenstock J, Gauldie J. Effect of histamine on proliferation of normal human adult lung fibroblasts. Thorax 1988; 43:552-8.
28. Kupietzky A, Levi-Schaffer F. The role of mast cell-derived histamine in the closure of an in vitro wound. Inflamm Res 1996; 45:176-80.
29. Claman HN, Choi KL, Sujansky W, Vatter AE. Mast cell 'disappearance' in chronic murine graft-vs-host disease (GVHD)-ultrastructural demonstration of 'phantom mast cells'. J Immunol 1986; 137:2009-13.
30. Choi KL, Giorno R, Claman HN. Cutaneous mast cell depletion and recovery in murine graft-vs-host disease. J Immunol 1987; 135:4093-101.
31. Dvorak AM, Kissell S. Granule changes of human skin mast cells characteristics of piecemeal degranulation and associated with recovery during wound healing in situ. J Leukoc Biol 1991; 49:197-210.
32. Levi-Schaffer F, Rubinchik E. Activated mast cells are fibrogenic for 3T3 fibroblasts. J Invest Dermatol 1995; 104:999-1003.
33. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-vs-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57:267-76.
34. Chosidow O, Bagot M, Vernant JP et al. Sclerodermatous chronic graft-vs-host disease. Analysis of seven cases. J Am Acad Dermatol 1992; 26:49-55.
35. Jaffe BD, Claman HN, Huff JC, Clark RA. Chronic graft-vs-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol 1983; 77:1-12.
36. Claman HN, Jaffe BD. Chronic graft-vs-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 1985; 94:73-84.
37. Janin-Mercier A, Saurat JH, Bourges M, Sohier J, Jean LD, Gluckman E. The lichen planus like and sclerotic phases of the graft vs. host disease in man: an ultrastructural study of six cases. Acta Derm Venerol 1981; 61:187-93.
38. Levi-Schaffer F, Mekori YA, Segal V, Claman HN. Histamine release from mouse and rat mast cells cultured with supernatants from chronic murine graft-vs-host splenocytes. Cell Immunol 1990; 127:146-58.
39. Levi-Schaffer F, Segal V, Mekori YA, Claman HN, Hammel I. Morphological evidence for chronic mast cell activation after prolonged exposure with supernatants from chronic graft-vs-host splenocytes. Immunol Lett 1991; 27:13-8.
40. Nagler A, Segal V, Slavin S, Levi-Schaffer F. Ketotifen therapy in chronic graft-vs-host disease (cGVHD): effect on mast cells and fibroblasts. Clin Exp Immunol 1995; 100:529-35.
41. Levi-Schaffer F, Segal V, Barak V, Rubinchik E, Nagler A. Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human graft-vs-host disease. Exp Hematol 1996 (in press).
42. Levi-Schaffer F, Segal V, Shalit M. Effects of interleukins on connective tissue type mast cells co-cultured with fibroblasts. Immunology 1991; 72:174-80.
43. Rubinchik E, Norris AA, Levi-Schaffer F. Modulation of histamine release from mast cells by IL-2 is affected by nedocromil sodium. Int J Immunopharmacol 1995; 17:563-71.
44. Levi-Schaffer F, Goldenhersch MA, Segal V, Nagler A. Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease. Bone Marrow Transplant 1997; in press.
45. Levi-Schaffer F, Garbuzenko E, Pickholtz D, Nagler A. Eosinophils and fibrosis. In: Basomba A, Sastre J, eds. Proceedings of the XVI European Congress of Allergology and Clinical Immunology, Bologna, Italy: 1995:111-08.
46. Moqbel R, Levi-Schaffer F, Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol 1994; 94:1183-8.
47. Janin A, Torpier G, Courtin P et al. Segregation of eosinophil proteins in alveolar macrophage compartments in chronic eosinophilc pneumonia. Thorax 1993; 48:57-62.
48. Samoszuk MK, Espinoza FP. Deposition of autofluorescent eosinophil granules in pathologic bone marrow biopsies. Blood 1987; 70:597-99.
49. Pincus SH, Ramesh KS, Wyler DJ. Eosinophils stimulate fibroblast DNA synthesis. Blood 1987; 70:572-4.
50. Shock A, Rabe KF, Dent G et al. Eosinophils adhere to and stimulate replication of lung fibroblasts 'in vitro'. Clin Exp Immunol 1991; 86:185-90.
51. Hernnas J, Sarnstrand B, Lindroth P, Peterson CG, Venge P, Malmstrom A. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol 1992; 59:352-63.
52. Garbuzenko E, Pickholtz D, Levi-Schaffer F. Effect of mast cells and eosinophils on human fibroblast proliferation and collagen synthesis. Allergy 1996; 51:18.
53. Birkland TP, Cheavens MD, Pincus SH. Human eosinophils stimulate DNA synthesis and matrix production in dermal fibroblasts. Arch Dermatol Res 1994; 286:312-8.
54. Bradding P. Human mast cell cytokines. Clin Exp Allergy 1996; 26:13-19.
55. Silver RM, Ludwicka A, Hampton M et al. A murine model of the eosinophilia-myalgia syndrome induced by 1,1′-ethylidenebis (L-tryptophan). J Clin Invest 1994; 93:1473-80.
56. Takagi K, Harada T, Ishikawa E. Kimura's disease (eosinophilic lymphfolliculoid granuloma). Nippon Rinsho 1993; 51:785-8.
57. Levi-Schaffer F, Temkin V, Weg VB, Zilberman Y. Mast cell sonicates enhance eosinophil survival: a GM-CSF mediated effect. J Allergy Clin Immunol 1996; 97:271.
58. Weg VB, Temkin V, Levi-Schaffer F. Mast cell sonicates activate eosinophil for cytokine release: effect of dexamethasone. J Allergy Clin Immunol 1996; 97:272.
59. Gurram M, Pahwa S, Fried M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994; 73:493-6.
60. Feghali CA, Bost KL, Boulware DW, Levy LS. Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994; 17:309-18.
61. Fries KM, Felch ME, Phipps RP. Interleukin-6 is an autocrine growth factor for murine lung fibroblast subsets. Am J Respir Cell Mol Biol 1994; 11:552-60.
62. San Antonio JD, Lander AD, Wright TC, Karnovsky MJ. Heparin inhibits the attachment and growth of Balb/c-3T3 fibroblasts on collagen substrata. J Cell Physiol 1992; 150:8-16.
63. Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. FASEB J 1994; 8:854-61.
64. Rubinchik E, Levi-Schaffer F. Interleukin-2 inhibits 3T3 fibroblast proliferation. Life Sci 1996; 58:1509-19.